http://www.bostonscientific.com/en-US/home.html
Boston Scientific put its turnaround in the rear view mirror in 2016 and set its sights on accelerating and stabilizing that growth by expanding into high-growth adjacent markets.
“Our investment strategy has focused on diversifying our portfolio and shifting the growth profile of the company toward higher-growth markets and focusing on globalization,” a company spokeswoman told us, noting that once-core products likes stents, pacemakers and defibrillators are now only 50% of the total offering.
“We expect that to be about a third as we continue to grow with our robust pipeline,” she said, adding that nearly half of Boston Scientific’s sales come from global markets.
A June 2016 restructuring meant little net change to total employment numbers, as BSC looked to pare its pre-tax expenses by $115 million to $150 million by the end of 2020.